Today: 20 May 2026
Cameco Stock Rockets on $80B US Nuclear Reactor Deal — Is the Uranium Bull Market Here to Stay?
28 October 2025
2 mins read

Cameco Stock Rockets on $80B US Nuclear Reactor Deal — Is the Uranium Bull Market Here to Stay?

  • $80B Reactor Partnership: On Oct. 28, Cameco (NYSE: CCJ) and partner Brookfield announced a U.S. government–backed deal to finance and build at least $80 billion of new Westinghouse nuclear reactors reuters.com ca.investing.com. The agreement “aims to accelerate nuclear power deployment” and meet surging electricity demand from AI and data centers reuters.com, reinforcing the current nuclear revival.
  • Shares Surge: CCJ stock jumped roughly 10–15% on the news reuters.com ca.investing.com, continuing a massive 2025 rally. Year-to-date CCJ is up ~65–80% (vastly outperforming the S&P 500) on tight uranium supply and rising demand ts2.tech ts2.tech. Analysts note Cameco’s “low-cost, diversified mines and fuel business” make it a relatively safe play that “earns profits now and will steadily benefit if uranium prices stay strong” ts2.tech.
  • High Uranium Prices: Uranium spot prices are trading in the mid-$70s per pound ts2.tech (multi-year highs), and many firms forecast further gains toward $80–$100/lb ts2.tech. Supply is tightening – Cameco recently cut its 2025 production guidance to ~14–15M lbs (from 18M) due to mine delays mining.com, and Kazakhstan’s Kazatomprom has also curbed output. One analysis notes “revived interest in nuclear power… is providing the demand” even as supply has tightened ts2.tech.
  • Pro-Nuclear Policies: Global policy tailwinds are strong. The U.S. has poured billions into advanced reactors (FY2024 DOE budget ~$50B) and passed laws to speed SMR approvals . Europe, Asia and other regions are also greenlighting new projects . Reuters reports the $80B deal aligns with President Trump’s May nuclear executive order . Such support has revived dozens of projects worldwide , bolstering Cameco’s outlook.
  • Analysts Bullish: Wall Street is largely positive on CCJ. MarketBeat notes a consensus analyst “Buy” rating, with an average price target around $90 marketbeat.com. (By comparison, CCJ closed ~$88 on Oct. 24 cameco.com.) Research reports highlight Cameco’s industry-leading reserves, low debt and long-term contracts for stable cash flow ts2.tech. CEO Tim Gitzel calls the new partnership “value creation” that will enhance Cameco’s fuel supply role ca.investing.com. At the same time, experts caution that nuclear projects have long lead times and regulatory risks ts2.tech, so investors are watching execution of reactor plans closely.
  • Next Steps: Cameco will report Q3 results on Nov. 5, 2025 marketscreener.com. Investors will look for updates on sales and costs – after strong H1 results, management said its “balanced and disciplined strategy” can weather the McArthur River mining delays cameco.com. Given the uranium bull thesis (WNA sees demand +28% by 2030 reuters.com) and Cameco’s position, most analysts remain optimistic about CCJ’s medium-term trajectory.

In sum, Cameco is squarely in the spotlight of today’s nuclear energy boom. The U.S. reactor pact and robust uranium fundamentals have driven a powerful rally. Industry watchers say Cameco’s vast reserves and fuel-cycle assets make it a go-to name for playing the “second act” of nuclear power ts2.tech ts2.tech. However, as one commentator puts it, investors should still “weigh valuations and monitor” policy and supply trends ts2.tech. With uranium prices up and governments supporting nuclear, Cameco’s near-term outlook is bright – but execution of these big reactor plans and any global supply shifts will ultimately determine whether CCJ can sustain its gains.

Sources: Recent Cameco press releases and filings ; Reuters and investing.com coverage of the $80B reactor deal ; TS2.tech and NAI500 market analyses ; uranium industry data ; MarketBeat and company data .

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?
Previous Story

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

Oil Prices Poised to Plunge in 2026 as Permian Boom Kicks In
Next Story

Oil Prices Poised to Plunge in 2026 as Permian Boom Kicks In

Go toTop